RxDoctor Payments Data

Anju Nayar, MD

Psychiatry · Cherry Hill, NJNPI 1649363409

Payments from drug & device makers

$933in general payments, 2019–2025

Across 67 payments — averaging $13.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$358
  • Johnson & Johnson$166
  • Otsuka America Pharmaceutical, Inc.$118
  • Sunovion Pharmaceuticals Inc.$115
  • Neurocrine Biosciences, Inc.$36
  • Vanda Pharmaceuticals Inc.$26
  • plus $115 from 8 others

What the payments were for

  • Food & beverage$933100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$933 in reported general payments places this provider in the 70th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$54,462
Medicare patients
72
Services billed
826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$161,469
VraylarCariprazine Hcl27$40,357
Invega SustennaPaliperidone Palmitate12$38,949
Lurasidone Hcl24$6,412
FetzimaLevomilnacipran Hcl13$6,408
Bupropion XlBupropion Hcl245$5,485
VyvanseLisdexamfetamine Dimesylate11$4,252
Aripiprazole121$3,356
Duloxetine Hcl173$3,185
Clonazepam382$3,115
Venlafaxine Hcl ErVenlafaxine Hcl152$2,608
Quetiapine Fumarate214$2,499
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine110$2,463
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$2,461
Vilazodone Hcl19$2,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$36$161,46911 claims
AbbVieVraylar, Fetzima$358$46,76540 claims
Johnson & JohnsonInvega Sustenna$166$38,94912 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$23$4,25211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →